Anavex Life Sciences Corp (AVXL)
4.12
-0.01
(-0.24%)
USD |
NASDAQ |
Jul 03, 16:00
Anavex Life Sciences Research and Development Expense (TTM): 38.28M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 38.28M |
| December 31, 2023 | 39.58M |
| September 30, 2023 | 42.97M |
| June 30, 2023 | 44.29M |
| March 31, 2023 | 43.28M |
| December 31, 2022 | 41.33M |
| September 30, 2022 | 37.92M |
| June 30, 2022 | 35.91M |
| March 31, 2022 | 35.60M |
| December 31, 2021 | 33.71M |
| September 30, 2021 | 32.98M |
| June 30, 2021 | 29.72M |
| March 31, 2021 | 27.48M |
| December 31, 2020 | 26.81M |
| September 30, 2020 | 25.23M |
| June 30, 2020 | 23.84M |
| March 31, 2020 | 22.87M |
| December 31, 2019 | 22.90M |
| September 30, 2019 | 22.26M |
| June 30, 2019 | 21.96M |
| March 31, 2019 | 19.20M |
| December 31, 2018 | 16.36M |
| September 30, 2018 | 13.34M |
| June 30, 2018 | 12.77M |
| March 31, 2018 | 12.08M |
| Date | Value |
|---|---|
| December 31, 2017 | 11.32M |
| September 30, 2017 | 10.67M |
| June 30, 2017 | 10.20M |
| March 31, 2017 | 9.060M |
| December 31, 2016 | 7.658M |
| September 30, 2016 | 6.779M |
| June 30, 2016 | 4.160M |
| March 31, 2016 | 3.800M |
| December 31, 2015 | 3.117M |
| September 30, 2015 | 2.272M |
| June 30, 2015 | 1.869M |
| March 31, 2015 | 1.335M |
| December 31, 2014 | 1.046M |
| September 30, 2014 | 0.7324M |
| June 30, 2014 | 0.4856M |
| March 31, 2014 | 0.2596M |
| December 31, 2013 | 0.142M |
| September 30, 2013 | 0.2638M |
| June 30, 2013 | 0.2795M |
| March 31, 2013 | 0.6345M |
| December 31, 2012 | 1.064M |
| September 30, 2012 | 2.654M |
| June 30, 2012 | 3.133M |
| March 31, 2012 | 3.517M |
| December 31, 2011 | 3.817M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
22.26M
Minimum
Sep 2019
44.29M
Maximum
Jun 2023
33.00M
Average
33.71M
Median
Dec 2021
Research and Development Expense (TTM) Benchmarks
| Ventyx Biosciences Inc | 174.08M |
| Checkpoint Therapeutics Inc | 36.24M |
| Biogen Inc | 2.344B |
| Amicus Therapeutics Inc | 139.21M |
| InfuSystems Holdings Inc | -- |